Tilbake til søkeresultatene

BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering

An integrated approach for epigenetic risk assessment and biomarker development for breast cancer in prospective cohorts

Tildelt: kr 1,6 mill.

Prosjektnummer:

237288

Søknadstype:

Prosjektperiode:

2014 - 2018

Geografi:

Epigenetikk er forandringer i genuttrykk som gir korttidstilpasning til endringer i ytre miljøbetingelser og et stressfylt miljø, og som ikke har sin årsak i nukleotidsekvensen i DNA, men skyldes bare kjemiske endringer i nukleinsyrer eller DNA-bindende proteiner. Epigenetikk i dag representerer en av de mest spennende områdene i life science forskning. Epigenomikk er studiet av alle epigenetiske endringer i genomet. Tilgjengeligheten av innovative verktøy som forenkler epigenetic studier er avgjørende for utvikling av nye sykdomsrelaterte biomarkører. Den EpiMark konsortium vil bidra til å oppnå dette, samt bidra til ytterligere vår forståelse av utviklingen av brystkreft.

Despite the availability of new chemotherapeutic agents and progress in screening, breast cancer is still the most common cancer affecting women in developed countries. Epigenetic changes are ubiquitous in primary breast cancer, but less is known about th e dietary/lifestyle and endogenous determinants of these changes. This project?s underlying hypothesis is that environmental factors and endogenous cues trigger changes in the methylome, that these changes contribute to the onset of breast cancer, and tha t they can serve as biomarkers in primary and secondary prevention. The project?s three main objectives are: (1) to identify DNA methylome changes in breast cancer and surrogate tissue using a large sample of several thousand subjects from a prospective c ohort, (2) to establish dietary/lifestyle and endogenous determinants of epigenetic changes, and (3) to assess the predictive value of methylation markers in clinical settings. This project is based on the European Prospective Investigation into Cancer an d Nutrition (EPIC) cohort, a study conducted in 23 centres in 10 European countries, and will use powerful epigenomic technology for biomarker discovery and validation. This study will provide unique insights into the role of risk factors in driving the e pigenetic changes that are associated with breast cancer, and will reveal potential targets for biomarker discovery and future preventative strategies. Thus, the proposal is highly relevant to the main objectives of this call: providing a scientific basis for primary and secondary prevention of cancer.

Aktivitet:

BEHANDLING-God og treffsikker diagnostikk, behandling og rehabilitering